Ingham Institute for Applied Medical Research, Liverpool, Sydney, New South Wales, Australia.
Am J Gastroenterol. 2013 Jul;108(7):1082-93. doi: 10.1038/ajg.2013.94. Epub 2013 Apr 16.
The role of human papillomavirus (HPV) in Barrett's esophagus (BE) remains unclear. The few studies that have previously investigated HPV and esophageal adenocarcinoma (EAC) or BE have produced either negative data or positive results of doubtful clinical/etiological significance or have detected only low-risk HPV types. We therefore prospectively determined the prevalence of biologically active HPV in esophageal epithelium of patients representing the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
HPV DNA was estimated by nested PCR and viral transcriptional activity detected by E6/7 oncogene mRNA expression and p16INK4A immunohistochemistry in fresh frozen and paraffin-embedded esophageal biopsies of patients with BE, Barrett's dysplasia (BD), and EAC, as well as controls. Biopsies were obtained from the transformation zone (squamocolumnar junction (SCJ)) and the lesion, or corresponding site in controls, i.e., 2 cm above the gastroesophageal junction (GEJ).
Of the 261 patients, 81 were positive for HPV DNA. In controls and BE, the virus was mostly detected at the transformation zone. Compared with controls (18.0%), HPV positivity was significantly more common in BD (68.6%, incidence rate ratio (IRR) 2.94, 95% confidence interval (CI) 1.78-4.85, P<0.001) and EAC (66.7%, IRR 2.87, 95% CI 1.69-4.86, P<0.001), but not in BE (22.1%, IRR 1.06, 95% CI 0.60-1.85, P=0.85). Of the patients, 92.6% were high-risk (HR) HPV, i.e., types 16 and 18. Again, p16INK4A positivity was greatest in BD and EAC and much less in BE patients (44.1%, IRR 17.0 (95% CI 4.86-59.6, P<0.001), 44.4%, 17.0 (95% CI 4.87-59.4, P<0.001), and 10.6%, 3.93 (95% CI 1.01-15.3, P=0.048) respectively). In 66 HPV DNA-positive patients tested for E6/E7 mRNA, none of the control (n=16) or BE (n=13) individuals were positive, whereas 9/22 BD and 9/15 EAC patients demonstrated oncogene expression (P<0.001). When HPV DNA, p16INK4A, and E6/E7 mRNA were all positive, there was a very strong association with disease severity (SCJ: odds ratio (OR) 104, 95% CI 20.3-529, P<0.001; lesion: OR 62.2, 95% CI 12.4-311, P<0.001) than when all were negative.
Transcriptionally active HR-HPV was strongly associated with BD and EAC, but was largely biologically irrelevant in BE and controls, suggesting a potential role in esophageal carcinogenesis. These data provide robust justification for further detailed longitudinal, interventional, and molecular studies.
人乳头瘤病毒(HPV)在 Barrett 食管(BE)中的作用尚不清楚。之前少数研究过 HPV 与食管腺癌(EAC)或 BE 的关系,结果要么是阴性数据,要么是具有可疑临床/病因学意义的阳性结果,要么只检测到低危型 HPV 类型。因此,我们前瞻性地确定了代表 Barrett 化生-异型增生-腺癌序列的患者食管上皮中具有生物活性的 HPV 的患病率。
通过巢式 PCR 估计 HPV DNA,通过 E6/7 癌基因 mRNA 表达和 p16INK4A 免疫组化检测新鲜冷冻和石蜡包埋食管活检中的病毒转录活性,这些活检来自患者的 BE、Barrett 异型增生(BD)和 EAC 以及对照。活检取自转化区(鳞柱状交界处(SCJ))和病变处,或对照物的相应部位,即胃食管交界处(GEJ)上方 2cm 处。
在 261 名患者中,有 81 名 HPV DNA 阳性。在对照组和 BE 中,病毒主要在转化区检测到。与对照组(18.0%)相比,BD(68.6%,发病率比(IRR)2.94,95%置信区间(CI)1.78-4.85,P<0.001)和 EAC(66.7%,IRR 2.87,95% CI 1.69-4.86,P<0.001)中 HPV 阳性更为常见,但在 BE 中则不然(22.1%,IRR 1.06,95% CI 0.60-1.85,P=0.85)。在患者中,92.6%为高危(HR)HPV,即 16 型和 18 型。同样,p16INK4A 阳性在 BD 和 EAC 中最高,在 BE 患者中则明显较少(44.1%,IRR 17.0(95% CI 4.86-59.6,P<0.001),44.4%,17.0(95% CI 4.87-59.4,P<0.001)和 10.6%,3.93(95% CI 1.01-15.3,P=0.048))。在 66 名 HPV DNA 阳性的患者中进行了 E6/E7 mRNA 检测,对照组(n=16)或 BE 组(n=13)中均未检测到任何个体呈阳性,而 22 名 BD 患者中有 9 名和 15 名 EAC 患者中有 9 名表现出致癌基因表达(P<0.001)。当 HPV DNA、p16INK4A 和 E6/E7 mRNA 均为阳性时,与疾病严重程度的相关性非常强(SCJ:比值比(OR)104,95%CI 20.3-529,P<0.001;病变:OR 62.2,95%CI 12.4-311,P<0.001),而当所有均为阴性时则较弱。
转录活跃的 HR-HPV 与 BD 和 EAC 强烈相关,但在 BE 和对照组中在很大程度上与生物学无关,这表明其在食管癌变中可能具有潜在作用。这些数据为进一步详细的纵向、干预和分子研究提供了有力的依据。